FDA approves first oral carbapenem for complicated urinary tract infections

Hard-to-treat urinary tract infections (UTIs) now have a new treatment option following the approval of a new antibiotic, tebipenem pivoxil hydrobromide, marketed as Utebzi, for complicated UTIs, including serious kidney infections such as pyelonephritis.

The US Food and Drug Administration (FDA) approval marks a significant milestone as it is the first oral medication in the carbapenem class of antibiotics to be authorised for use.

The introduction of an oral version represents a major shift in treatment, potentially allowing selected patients to receive care without hospital admission, improving convenience and reducing healthcare costs and pressure on inpatient services.

The FDA approved the drug for adults with complicated UTIs caused by susceptible bacteria, including Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis. These organisms are among the most common causes of urinary tract infections, especially in cases where infections are severe, recurrent, or resistant to standard antibiotics.

Complicated UTIs are often harder to treat than simple infections, particularly in patients with underlying health conditions such as diabetes, structural abnormalities in the urinary tract, or weakened immune systems.

In many of these cases, patients require prolonged hospitalisation for intravenous antibiotics. The availability of an effective oral carbapenem may help reduce hospital stays and offer an alternative treatment pathway for some patients.

Clinical trial results supporting the approval showed that oral tebipenem pivoxil was effective in treating infections caused by susceptible organisms, with outcomes comparable to standard intravenous therapies in carefully selected patients. Researchers also highlighted its potential role in antimicrobial stewardship, where it could be used either as an alternative oral option or as a step-down treatment after initial IV therapy.

Despite its benefits, health experts stress the importance of careful use. Carbapenems are considered critical antibiotics in the fight against antimicrobial resistance, and inappropriate or widespread use could reduce their effectiveness over time. For this reason, the drug is expected to be reserved for patients who have limited or no suitable oral antibiotic options.

The approval comes amid rising global concern over antibiotic resistance, which is making many infections increasingly difficult to treat with existing medicines. In this context, the development of new treatment options, especially oral therapies, is seen as an important step forward in expanding clinical choices.

The approval of tebipenem pivoxil hydrobromide represents a major advancement in the treatment of complicated UTIs, offering a new and more flexible option for patients while reinforcing the need for responsible antibiotic use to protect its long-term effectiveness.

Urinary tract infections (UTIs) are among the most common bacterial infections globally, affecting an estimated 150 to 250 million people each year. Women are disproportionately affected, with about half expected to experience at least one UTI in their lifetime. UTIs also account for millions of healthcare visits annually worldwide, and around 20 to 30 per cent of women experience recurrent infections after their first episode.

In Kenya, UTIs are also a major public health concern and are frequently reported among the top outpatient infections treated in health facilities. They are estimated to account for about 10 to 15 per cent of outpatient cases, with higher rates in some maternity and pediatric settings.

Women of reproductive age are the most affected group, and studies show that urinary tract infections are also common during pregnancy, with prevalence in some hospitals ranging from about 15 to over 25 per cent, depending on the population studied.

Across both global and local settings, UTIs remain highly prevalent but largely treatable infections. However, challenges such as delayed diagnosis and increasing antibiotic resistance continue to contribute to recurrent and more complicated cases, particularly in vulnerable populations.